MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Evoke Pharma Market Cap 2011-2026 | EVOK
As of March 24, 2026 Evoke Pharma has a market cap of $ 36.6 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Evoke Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.24 M | 9.81 M | 20.5 M | 67.5 M | 32.6 M | 46.8 M | 40.7 M | 26.6 M | 20.5 M | 39 M | 24.3 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 67.5 M | 2.24 M | 30 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
142 M | $ 0.97 | 2.36 % | $ 104 M |  Canada |
 |
Aurora Cannabis
ACB
|
915 M | $ 3.31 | 1.53 % | $ 86.3 M | Canada |
 |
China Pharma Holdings
CPHI
|
4.54 M | $ 0.63 | 16.11 % | $ 11 M |  China |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
3.63 B | $ 2.52 | 5.44 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
139 M | $ 8.05 | -1.71 % | $ 412 M | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 3.05 | 7.77 % | $ 42.9 M | USA |
 |
Bausch Health Companies
BHC
|
3.38 B | $ 5.1 | 1.8 % | $ 1.86 B | Canada |
 |
Harrow Health
HROW
|
1.93 B | $ 34.0 | 2.16 % | $ 1.25 B | USA |
 |
Assertio Holdings
ASRT
|
75.4 M | $ 14.0 | 4.71 % | $ 89.6 M | USA |
 |
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
271 M | $ 4.68 | 0.86 % | $ 302 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 22.65 | 2.44 % | $ 1.05 B | USA |
 |
OrganiGram Holdings
OGI
|
382 M | $ 1.36 | - | $ 402 M | Canada |
 |
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
82.8 M | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 5.86 | -3.46 % | $ 231 M | USA |
 |
Rockwell Medical
RMTI
|
35.5 M | $ 1.02 | -2.86 % | $ 23.8 M | USA |
 |
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
889 K | $ 1.36 | 0.74 % | $ 3.37 M | Canada |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 0.88 | -6.09 % | $ 43.9 M | USA |
 |
Solid Biosciences
SLDB
|
623 M | $ 7.14 | 1.56 % | $ 625 M | USA |
 |
Organogenesis Holdings
ORGO
|
415 M | $ 2.47 | 3.65 % | $ 325 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
1.96 B | $ 9.57 | 3.46 % | $ 1.33 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 2.55 | 4.94 % | $ 3.16 M | USA |
 |
Tilray
TLRY
|
1.19 B | $ 6.45 | 3.86 % | $ 3.99 B | Canada |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
23.9 M | $ 2.31 | 3.12 % | $ 24.1 M | USA |
 |
Veru
VERU
|
108 M | $ 2.3 | 1.32 % | $ 310 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 13.29 | 0.68 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
1.68 M | $ 0.76 | 11.88 % | $ 3.28 M | USA |
 |
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |